Hydrogen ion dynamics and the Na+/H+ exchanger in cancer angiogenesis and antiangiogenesis

British Journal of Cancer

Volumn 89, Issue 8, 2003, Pages 1395-1399

  Orive, G ^a   Reshkin, S J ^b   Harguindey, S ^c   Pedraz, J L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF BARI   (Italy)

^c Centro Medico La Salud   (Spain)

Author keywords

Angiogenesis; Antiangiogenesis; Antiporter; Na+ H+; Oncogenesis; pH regulation

Indexed keywords

AMILORIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAPTOPRIL; EDELFOSINE; GENISTEIN; NATRIURETIC FACTOR; PROTON; SODIUM PROTON EXCHANGE PROTEIN; SQUALAMINE; STAUROSPORINE; SULINDAC; SURAMIN; WARFARIN;

ANGIOGENESIS; CANCER CONTROL; CANCER GROWTH; CANCER RESEARCH; CELL PH; DRUG SELECTIVITY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; SHORT SURVEY; SIDE EFFECT;

ACID-BASE EQUILIBRIUM; ANGIOGENESIS INHIBITORS; CELL DIVISION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; HYDROGEN-ION CONCENTRATION; NEOVASCULARIZATION, PATHOLOGIC; SODIUM-HYDROGEN ANTIPORTER;

EID: 0242491504     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601286     Document Type: Short Survey

References (38)

1. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, Ellis LM (1999) Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1 beta. Br J Cancer 80: 1506-1511
2. + antiport in a murine T cell. J Immunol 143: 4000-4008
3. Clark JW, Chabner BA (1995) Suramin and prostate cancer: where do we go from here? J Clin Oncol 13: 2155-2157
4. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW (2002) A novel mechanism of tumourigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9: 12-16
5. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C (2001) Hepatocyte growth factor/scatter factor-induced activation of MEK and P13K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918
6. Doppler W, Jaggi R, Groner B (1987) Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3T3 cells causes intracellular alkalinization and cell cycle progression. Gene 54: 147-153
7. El Awad B, Kreft B, Wolber EM, Hellwig-Burgel T, Metzen E, Fandrey J, Jelkman W (2000) Hypoxia and interleukin-1 beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 58: 43-50
8. Eliceiri BP, Cheresh DA (2001) Adhesion events in angiogenesis. Curr Opin Cell Biol 13: 563-568
9. Evans DM, Sloan-Stakleff K (2000) Supression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am Surg 66: 460-464
10. Ferreira CG, Tolis C, Giaccone C (1999) p53 and chemosensitivity. Ann Oncol 10: 1011-1021
11. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
12. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235: 442-447
13. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S (1996) Microvessel count products survival in uveal melanoma. Cancer Res 56: 2900-2903
14. +-antiporter in growth stimulation by Ha-Ras. In Plasma Oxidoreductases in the Control of Animal and Plant Growth, Crane FL, Low H (eds) pp 369-371. New York: Plenum Press
15. + antiport inhibitor amiloride. Oncologia 25: 472-476
16. +-mediated unifying approach: pH-related and pH-unrelated mechanisms. Crit Rev Oncogenesis 6: 1-33
17. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
18. Kim YB, Han JY, Kim TS, Kim PS, Chu YC (2000) Overexpression of c-H-ras p21 is correlated with vascular endothelial growth factor expression and neovascularization in advanced gastric carcinoma. J Gastroenterol Hepatol 15: 1393-1399
19. + exchange and ERK1/2. Circul Res 83: 824-831
20. Liotta L, Kleinerman J, Saidel G (1974) Quantitative relationships of intravascular tumour cells, tumour vessel, and pulmonary metastases following tumour implantation. Cancer Res 34: 997-1004
21. Macchiarini P, Fontanini G, Hardn MJ, Sguartini F, Angeletti CA (1992) Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 340: 145-146
22. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y, Kondo Y, Sowa M (1995) Tumour angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13: 477-481
23. Maruyama K, Mori Y, Murasawa S, Masaki H, Takahashi N, Tsutusmi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Shibuya M, Inada M, Matsubara H, Iwasaka T (1999) Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases. J Mol Cell Cardiol 31: 607-617
24. Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC (2000) Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol 2: 318-325
25. O'Really MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogeneous inhibitor of angiogenesis and tumour growth. Cell 88: 277-285
26. O'Really MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
27. + exchanger, NHE1: structure, regulation and cellular actions. Ann Rev Pharmacol Toxicol 42: 527-552
28. Rak J, Filmus J, Finkenzeller G, Grugel S, Marmé D, Kerbel RS (1995) Oncogenes as inducers of tumour angiogenesis. Cancer Metast Rev 14: 263-277
29. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14: 2185-2197
30. + exchanger. Blood 95: 1427-1434
31. Rozhin J, Sameni M, Ziegler G, Slone, BF (1994) Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517-6525
32. Sills AK, Willians JM, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Cannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H (1998) Squalamine inhibits angiogenesis and solid tumour growth in vivo and perturbs embryonic vasculature. Cancer Res 58: 2784-2792
33. Sipos EP, Brem H (2000) Local antiangiogenic brain tumour therapies. J Neuro-Oncol 50: 181-188
34. Turk V, Turk B, Guncar G, Turk D, Kos J (2002) Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 42: 285-303
35. Vogt B, Frey FJ (1997) Inhibition of angiogenesis in Kaposis sarcoma by captopril. Lancet 349: 1143
36. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM (2001) Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153: 1023-1034
37. Webb SD, Sherratt JA, Fish RG (2001) Modelling tumour acidity and invasion. Novartis Found Symp 240: 169-181
38. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumour angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1-8